Abstract
Introduction Globally, measles remains a major cause of child mortality, and rubella is the leading cause of birth defects among all infectious diseases. In Mainland Tanzania, eliminating measles and rubella remains challenging due to geographical diversity, uneven healthcare facilities distribution, and socio-economic disparities across regions. This study aimed to explore the spatial distribution and associated factors of measles-rubella campaign coverage among children aged 9–59 months in Mainland Tanzania.
Methods A cross-sectional survey was conducted to assess the spatial distribution and factors influencing measles-rubella (MR) vaccination coverage among children aged 9–59 months in mainland Tanzania after the MR campaign implementation in February 2024. The spatial autocorrelation was used to assess vaccination coverage in a study area. Hotspot and cold-spot analysis were performed to describe the spatial cluster of measles-rubella vaccination campaign coverage in Mainland Tanzania based on Getis-Ord Gi* statistics. To identify factors associated with the campaign coverage, we used a multivariable logistic regression model.
Results The study involved 16,703 children, of whom 81.5% received the MR vaccine during the campaign. Vaccination coverage varied notably between regions, with Tabora and Pwani having a low coverage rate of 58.8% (95% CI: 51.3%-65.9%) and 61.0% (95% CI: 45.0%-75.0%) respectively. The Njombe and Mbeya demonstrating a high coverage rate of 97.4% (95% CI: 90.5%-99.3%) and 95.6% (95% CI: 90.9%-97.9%) respectively. The household wealth quintile and place of residence, caregiver’s education, caregiver’s age, and their marital status were associated with receiving MR vaccination during the campaign among children aged 9-59 months in Mainland Tanzania. Spatial distribution revealed significant clustering of vaccination coverage (Moran’s I = 0.34, p < 0.01). Hotspot analysis identified eight clusters with low coverage in —Tabora (five clusters) and Pwani (three clusters)— indicating higher proportions of unvaccinated children. Regions like Njombe and Mbeya were hotspots identified clusters with high vaccination coverage.
Conclusion This study highlights critical gaps in measles-rubella vaccination coverage in Mainland Tanzania, where regional disparities hinder the achievement of global targets. It stresses the importance of the caregiver’s education and household wealth, advocating for targeted interventions and localized research to address these challenges. To drive progress, integrating geospatial artificial intelligence (GeoAI), spatial data science, and satellite technology is crucial. These advanced tools enable real-time, high-resolution mapping, optimizing resource allocation, and identifying underserved areas. By leveraging these technologies, we can ensure data-driven, efficient interventions that leave no region behind, ultimately achieving universal vaccination coverage and protecting every child globally.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Ethical Committee of Ifakara Health Institute (IHI/IRB/No: 14-2024).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
